Novo Nordisk commits up to $2 billion to drug delivery startup Vivtex for development of oral metabolism drugs

Vivtex's technology uses artificial intelligence and high-throughput screening to identify drug ingredient combinations that can deliver peptides through gastrointestinal tissue. In addition to Novo Nordisk, the MIT spinout's partners include Astellas Pharma, Equillium and Orbis Medicines.

The post Novo Nordisk Commits Up to $2 Billion to Drug Delivery Startup Vivtex for Oral Metabolism Drug Development appeared first on MedCity News.